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Abstract Cell plasma membrane proteins, playing a crucial
role in cell malignant transformation and development, were
the main targets of tumor detection and therapy. In this study,
CyDye/biotin double-labeling proteomic approachwas adopted
to profile the membrane proteome of gastric cancer cell line
BGC-823 and paired immortalized gastric epithelial cell GES-
1. Real-time PCR,Western blotting, and immunohistochemical
staining were used to validate the differential expression of a
novel identified cell surfacemarker R-cadherin in gastric cancer
cells and tissues. Clinicopathological study and survival analy-
sis were performed to estimate its roles in tumor progression
and outcome prediction. Real-time PCR and Western blotting
showed that the expression level of R-cadherin in gastric cancer
were significantly lower than non-cancerous epithelial cell and
tissues. Clinicopathological study indicated that R-cadherin
was dominantly expressed on cell surface of normal gastric
epithelium, and its expression deletion in gastric cancer tissues
was associated with tumor site, differentiation, lymph node
metastasis, and pTNM (chi-square test, P<0.05). Those pa-
tients with R-cadherin positive expression displayed better
overall survivals than negative expression group (log-rank test,
P=0.000). Cox multivariate survival analysis revealed lacking
the expression of R-cadherin was a main independent predictor
for poor clinical outcome in gastric cancer (RR=5.680, 95 %
CI 2.250–14.341, P<0.01).We have established a fundamental
membrane proteome database for gastric cancer and identified
R-cadherin as a tumor differentiation and progression-related
cell surface marker of gastric cancer. Lacking the expression
of R-cadherin indicates poor prognosis in patients with gastric
cancer.
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Introduction
Gastric cancer (GC) is the second most common cause of
cancer death worldwide, although its incidence and mortality
have fallen dramatically over the last 50 years [1, 2].
According to the report of Global Cancer Statistics, nearly
three quarters of new cases of GC were diagnosed in
Asia and nearly half of these cases occurred in China
[3, 4]. Surgery remains the primary curative treatment
for GC [5, 6]; however, successful early detection and
radical resection of GC are hampered by lacking of highly
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sensitive and specific biomarkers [7]. Therefore, screening
more specific and sensitive early diagnostic biomarkers
is an effective way to improve overall outcomes of GC
[8, 9].
Despite significant improvements in systemic chemothera-
py over the last two decades, the prognosis of advanced GC
remains frustrating. As a part of comprehensive treatment for
gastric carcinoma, targeted chemotherapy and its related treat-
ment have wide development in recent years [10, 11].
Although progress has been made, thanks to trastuzumab in
partial HER2 positive GC, antiangiogenic drugs have pro-
duced conflicting results and EGFR-inhibitors have failed to
show major improvements [12, 13]. Discovering new thera-
peutic targets is a valuable and challenging work to improve
the prognosis of GC.
Circulating tumor cells (CTCs), acting as important
contributor and indicator for cancer metastasis [14], have
been studied as promising prognostic and predictive
tumor-derived biomarkers in the bloodstream of patients
with gastrointestinal malignancies [15–17]. Both the basic
magnetic bead separation and the latest micro-fluidic chips
applied for CTC enrichment and isolation all depend on
the immunological recognition of the cell surface markers
[18, 19]. Due to lacking of tumor-specific cell surface
markers, most of the current CTC detection methods were
obliged to base on the epithelial markers such as EpCAM.
Most of these epithelial markers might be Bblind^ to the
most dangerous cancer cells present in the circulation,
which may be going through epithelial-mesenchymal tran-
sition (EMT) and losing the expression of epithelial
markers [20, 21]. Therefore, exploring tumor-specific cell
surface marker is essential to improve the isolation effi-
ciency of CTCs from tumor patients.
Membrane proteins expressed on cell surface, which play
crucial roles in the whole process of cancer development, were
the major targets of the majority of antitumor reagents [22,
23]. A comprehensive membrane proteomic study of GC will
not only benefit for further understanding the mechanisms of
tumorigenesis of GC but also help to discover some novel
diagnostic and therapeutic targets [24].
As a kind of hydrophobic protein, extraction and enrich-
ment of cell surface proteins from tumor cells were extremely
difficult and the membrane proteomic database in GC is still
rare [25]. In order to explore the composition and charac-
teristics of cell surface proteins in GC, we adopted a
novel double-labeling membrane proteomic strategy to
profile the cell surface proteins in GC as described before
[26]. In our study, a series of membrane proteins including
a differential expressed protein R-cadherin were identified
from GC cell line BGC-823. In addition, we investigated
the relationship between R-cadherin expression and the
clinicopathological characteristics of GC. Its prognostic
value was also estimated in this study.
Materials and methods
Clinical samples
Twenty-five pairs of fresh frozen gastric adenocarcino-
ma and the adjacent non-cancerous mucosa tissues were
taken from tumor Biobank of The First Affiliated
Hospital of Xiamen University. Tissue microarray of human
GC (OD-CT-DgStm01-007 and HStm-Ade178Sur-01) was
obtained from National SOBC Biobank, which included 169
GC specimens, 80 samples of adjacent normal mucosa to
gastric carcinoma. Each patient had signed informed con-
sent for this research. This study protocol was approved
by the ethical committee of The First Affiliated Hospital
of Xiamen University.
Among these 169 GC samples, 117 of these patients were
men (69.2 %) and 52 (30.8 %) were women. The mean age of
the cohort was 59.5±11.2 years (median 60 years, range 28–
84 years). The levels of differentiation were used to classify
grading as the following: well and moderate (n=37, 21.9 %)
and poor and undifferentiated (n=132, 78.1 %). Tumor stag-
ing was assessed using the seventh edition of the tumor, node,
metastasis (TNM) system according to the Union for
International Cancer Control (UICC) and the American Joint
Committee on Cancer (AJCC). They were classified as IA
(n=10, 5.9 %), IB (n=14, 8.3 %), IIA (n=14, 8.3 %), IIB
(n=20, 11.8 %), IIIA (n=35, 20.7 %), IIIB (n=49, 29 %),
IIIC (n=9, 5.3 %), and IV (n=18, 10.7 %). One hundred
twenty-three cases were followed-up for at least 5 years.
Cell surface labeling and membrane protein separation
Human GC cell lines BGC-823, MGC-803, and SGC-7901,
were purchased from the Type Culture Collection of the
Chinese Academy of Sciences (Shanghai, China). The immor-
talized human gastric epithelial cell line GES-1 was obtained
from ATCC, USA. Cells were maintained in RPMI-1640 sup-
plemented with 10 % fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 μg/ml streptomycin in a humidified incuba-
tor with 5 % CO2 at 37 °C. All culture materials were pur-
chased from GIBCO, USA. Cell Surface Protein Isolation Kit
(89,881) is a product of Pierce, USA. CyDye™ DIGE fluors
dyes are all products of GE Healthcare, USA.
BGC-823 and GES-1 were cultured in 100-mm dishes until
reaching 70–80 % (approximately 6×106 cells/dish). Cells
were quickly washed thrice with ice-cold Hanks’ balanced salt
solution (HBSS) and then cultured in fresh serum-free RPMI-
1640 media for 16 h. After that, cells were washed thrice with
HBSS again and then incubated in the CyDye/Cy3 working
liquid (1×107 cells/nmol) for 15 min at 4 °C. After washed by
HBSS thrice to remove the unlabeled Cy3, 10-ml sulfo-NHS-
SS-biotin working solutions which provided by Cell Surface
Protein Isolation Kit was added to the Cy3-tagged cells and
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rocked gently for 30 min at 4 °C to ensure the efficient of
labeling reaction. In order to stop labeling reactions, 1 ml of
L-lysine solution (10 mmol) and 10-ml quenching solution
(PBS with 100 mmol L-glycine) was added to each culture
cell. The double-tagged cells were scraped from dishes gently
and transferred into 50-ml centrifuge tube to collect cell
pellets (500g for 3 min at 4 °C). Cell pellets were washed
thrice with 5 ml of TBS gently and dissolved in 500-μl
lysis buffer (7 M urea, 2 M thiourea, 2 % CHAPS, 2 %
Triton-X, 2 % ampholyte, 1%DTT). Next, the cell lysates
were centrifuged at 10,000g for 2 min at 4 °C, then the
supernatant was incubated with 500 μl of slurry of avidin
beads in a column (prewashed thrice with wash buffer) for
60 min at room temperature on a rocking platform. The
column was centrifuged for 1 min at 1000g, and the flow-
through was collected. Then the beads were washed thrice
using 500 μl of wash buffer with 1 % protease inhibitors.
Finally, to elute the biotinylated proteins from the beads,
500 μl of sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) sample buffer (120 mmol/l Tris-
HCl pH 6.8, 20 % glycerin, 4 % SDS, 3 % β-
mercaptoethanol, 1 % protease inhibitors) was added to
the column and shook up and down for 60 min at room
temperature. Then the protein samples were collected fol-
lowing centrifugation for 1 min at 1000g. The extracted
proteins were quantified with Bradford’s reagent (Bio-Rad
laboratories, USA). Each 30-μg extracted membrane pro-
tein of BGC-823 and GES-1 was subjected to SDS-PAGE
gel (12.5 % separation gel and 5 % spacer gel) in three
lanes, followed by protein electrophoresis in GE MiniVE
(80 V for 3 h). The gel was fluorescent imaged and an-
alyzed with Typhoon imager 9410 (GE Healthcare) using
the 488-nm laser. After the fluorescence imaging, the gel
was post-stained by improved silver staining. The consis-
tent protein strips presented in both fluorescence and silver
dyeing were selected and matched and cut off from gel
for subsequent protein digestion and liquid chromatography-
tandem mass spectrometry (LC-MS/MS).
Protein digestion and LC-MS/MS
The silver-stained protein bands were detained with 30 %
ACN/100 mmol ammonium bicarbonate and dried in a
vacuum centrifuge. The in-gel proteins were reacted
with dithiothreitol (10 mmol DTT/100 mmol ammonium
bicarbonate) for 30 min at 56 °C, then alkylated with
iodoacetamide (200 mmol indoleacetic acid/100 mmol
ammonium bicarbonate) in the dark at room temperature
for 30 min. Gel bands were briefly rinsed with 100 mmol
ammonium bicarbonate and ACN, respectively. After that,
gel bands were digested overnight in 12.5 ng/μl trypsin
in 25 mmol ammonium bicarbonate. The peptides were
extracted three times with 60 % ACN/0.1 % trifluoroacetic
acid (TFA). The extracts were pooled and dried completely
by a vacuum centrifuge. Ettan™ MDLC system (GE
Healthcare, USA) was applied for desalting and separation
of tryptic peptides mixtures. In this system, samples were
desalted on RP trap columns (Zorbax 300 SB C18, Agilent
Technologies, USA) and then separated on a RP column
(150 μm i.d., 100 mm length, Column Technology Inc.,
Fremont, CA). Mobile phase A (0.1 % formic acid in
HPLC-grade water) and the mobile phase B (0.1 % formic
acid in acetonitrile) were selected. Twenty micrograms of
tryptic peptide mixtures was loaded onto the columns, and
separation was done at a flow rate of 2 μl/min by using a
linear gradient of 4–50 % buffer B for 50 min, 50–100 %
buffer B for 4 min, and 100 % buffer B for 6 min. LTQ
Velos (Thermo Scientific, USA) equipped with a micro-
spray interface was connected to the LC setup for eluted
peptides detection. Data-dependent MS/MS spectra were
obtained simultaneously. Each scan cycle consisted of one
full scan mass spectrum (m/z 300–1800) followed by 20
MS/MS events of the most intense ions with the following
dynamic exclusion settings: repeat count 2, repeat duration
30 s, and exclusion duration 90 s. MS/MS spectra were
automatically searched against the ipi.HUMAN.v3.53 using
the BioworksBrowser rev.3.1 (Thermo Electron, San Jose, CA).
Protein identification results were extracted from SEQUEST
out files with Build Summary. The peptides were constrained
to be tryptic and up to two missed cleavages were allowed.
Carbamidomethylation of cysteines was treated as a fixed
modification, whereas oxidation of methionine residues was
considered as variable modifications. The mass tolerance
allowed for the precursor ions was 2.0 Da and fragment ions
was 0.8 Da, respectively. The protein identification criteria
were based on Delta CN (≥0.1) and cross-correlation scores
(Xcorr, one charge ≥1.9, two charges ≥2.2, three charges ≥3.75).
Real-time quantitative PCR analysis (qRT-PCR)
Total RNA was extracted from culture cells, and 17 pairs of
fresh frozen gastric adenocarcinoma and the adjacent non-
cancerous mucosa tissues using Trizol reagent (Invitrogen,
USA) and then reverse transcripted to synthesize the first-
strand cDNA using Qiagen OneStep RT-PCR Kit (Qiagen,
USA) according to the instructions of the manufacturer. The
transcription levels were detected by THUNDERBIRD
SYBR qPCR Mix kit (TOYOBO, Japan) to monitor the
amplification. β-actin was used as an endogenous control
to normalize expression. PCR reactions in triplicate were
performed by PCR and initial denaturation at 95 °C for
5 min followed by 45 cycles, each consisting of 10 s at
95 °C, 20 s at 56 °C, and 20 s at 72 °C. The △Ct method
was adopted for analysis. First, the cycle number at the
threshold level of fluorescence (Ct) for each sample was
determined. Next, △Ct value was calculated.
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The 2−△△Ct method for relative quantification of gene
expression was used to determine the messenger RNA
(mRNA) expression levels.
Western blotting
In vitro cultured GC cells BGC-823, MGC-803, and SGC-
7901 and human gastric epithelial cell GES-1 were harvested
and lysed with RIPA lysis buffer (Beyotime, China) for
15 min on ice. One hundred milligrams tissue homogenate
of each frozen samples which came from eight pairs of fresh
frozen gastric adenocarcinoma and the adjacent non-
cancerous mucosa tissues were lyzed with RIPA lysis buffer
for 30 min on ice. After centrifugation at 13,000g for 10 min,
the concentration of proteins was measured using Bradford’s
reagent (Bio-Rad laboratories, USA). The protein samples
were denatured by boiling for 5 min and load onto 12.5 %
SDS-PAGE gel for electrophoresis. The proteins were trans-
ferred onto PVDF membrane (Millipore, USA) and incubated
in blocked solution (5 % nonfat milk in PBS) for 1 h at room
temperature. The anti-R-cadherin antibody (sc-6622, Santa
Cruz, USA) was added into blocking solution (1:1000) and
incubated at 4 °C for 16 h, followed bywashing and incubated
again with horseradish peroxidase-conjugated goat anti-rabbit
secondary antibodies (1:5000 dilution) for 1 h at room tem-
perature. Protein expression was normalized against β-actin
expression (Sigma, USA). Membranes were washed three
times for 5 min each; then, ECL kit (GE Healthcare, USA)
was applied for blot imaging according to the instructions of
the manufacturer.
Immunohistochemistry
Immunohistochemistry for R-cadherin was performed on tis-
sue microarray withMaxvison™ one step immunohistochem-
istry kit (Maixin Biotech, China). Briefly, tissue microarray
was dewaxed in xylene and brought to water through graded
alcohols. The antigens were repaired by high-pressure
cooking with citric acid repair solution (Maixin Biotech,
China, 1:100) and incubated with anti-R-cadherin antibodies
(1:100 dilution) at 4 °C overnight. After the antigen immuno-
reactivity, tissue microarray was washed thrice with PBS and
incubated with Maxvison™ for 15 min at room temperature
and rinsed thrice with PBS. The resultant immune peroxidase
activity was developed in DAB Detection Kit (Maixin
Biotech, China) for 3 min and counterstained with Harris’
hematoxylin. Appropriate negative controls were performed
by omitting the primary antibody. As positive controls,
paraffin-embedded liver sections with known immunoreactiv-
ity for R-cadherin were used. The percentages of positively
stained cells were obtained by counting at least 1000 cells in
each case by two independent experienced pathologists (S.T.
and S.V.) blinded to the clinical data with complete observer’s
agreement. Evaluation of immunostaining was analyzed ac-
cording to both the percentage of positive-staining cells and
the intensity of membrane staining. Intensity of staining was
graded on a scale of 0 to 3, with 0 recorded as no staining, 1 as
mild intensity, 2 as moderate intensity, and 3 as severe. Only
when the positive-staining cell is more than 10 % and its
intensity is greater than or equal to 2, it can be considered as
true R-cadherin positive cells.
Statistical analysis
For qRT-PCR analysis, student t test was used to assay the
differential expression of CDH4 in GC and control groups.
For tissue array immunohistochemistry analysis, chi-square
test was used to assay the association between R-cadherin
expression and clinicopathological variables. Kaplan-Meier
analysis and log-rank test were adopted for the plotting of
survival curves and for the univariate analysis of relationship
between R-cadherin expression and the prognosis of patients
with GC. Multivariate Cox regression analysis was used to
calculate the relative risk of R-cadherin expression in the over-
all survival of GC.
Results
Comprehensive profiling of membrane proteome in GC
cell line BGC-823
To explore the cell surface proteins in GC, a novel technology
to profile membrane proteome was carried out as described
before [26] in two human gastric cell lines (including cancer-
ous BGC-823 and non-cancerous GES-1) to make the results
more credible and comparable. Proteins on cell surface of both
BGC-823 and GES-1 cells can be specific labeled by fluores-
cent dye Cy3 and displayed a fluorescent dot or ring distrib-
uted in cell surface (Fig. 1a, b). The background was clean,
and there were not obvious cell rupture and lysis.
Following membrane protein extraction and SDS-PAGE
separation, the gel was scanned on a typhoon imager using
488-nm exciting light to resolve the fluorescent dye-labeled
membrane proteins of BGC-823 and GES-1. Results from
Fig. 1c showed BGC-823 and GES-1 cells displayed a similar
membrane proteome pattern, whereas, a great portion of these
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Fig 1 Fluorescence labeling and
separation of cell surface proteins
in BGC-823 and GES-1 cells.
a, b In situ labeling of cell surface
proteins with CyDyes DIGE
fluors in BGC-823 (a) and GES-1
cells (b). c–e Extracts of fluors-
labeled cell surface proteins from
BGC-823 (lines 1–3) and GES-1
(lines 4–6) were separated by
SDS-PAGE electrophoresis and
imaged by typhoon imager
scanner using 488-nm laser (c)
and silverstaining (d), and the
protein bands cut off for LC-MS












































Fig 2 Characteristics of 36 membrane proteins. aMolecular weight; b PI range; c Functional classification; d LC-MS of R-cadherin in cell surface of
BGC-823 GC cell
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Table 1 Characteristics of 36 cell plasma membrane proteins
ID Protein name MW PI TMDs GRAVY
Binding and structural proteins
IPI00796440 Peroxisomal membrane protein 2 (PXMP2) 41447.36 10.64 4 0.165
IPI00382470 Heat shock protein HSP 90-alpha (HSP 86) 98161.31 5.07 0 −0.754
IPI00022426 Protein AMBP 38999.49 5.95 0 −0.341
IPI00290035 Protocadherin-15 216069.72 4.94 1 −0.266
IPI00024034 Cadherin 4 (R-cadherin) 100280.55 4.65 1 −0.301
IPI00218795 L-selectin (SELL) 43617.75 6.96 1 −0.411
IPI00022759 Geranylgeranyl transferase type-1 subunit beta 42396.38 6.37 0 −0.272
IPI00290770 T-complex protein 1 subunit alpha 60462.75 6.1 1 −0.171
IPI00554711 Junction plakoglobin 81744.71 5.75 0 −0.157
Cell proliferation, differentiation and apoptosis related proteins
IPI00045337 Tumor necrosis factor receptor superfamily
member 13C (TNFRSF13C)
18863.8 8.47 2 −0.127
IPI00000690 Apoptosis-inducing factor 1, mitochondrial
(AIFM1)
66900.63 9.04 2 −0.227
IPI00013933 Desmoplakin 331774.4 6.44 0 −0.823
IPI00025753 Desmoglein-1 113715.49 4.9 1 −0.285
IPI00179330 Ubiquitin-40S ribosomal protein S27a (RPS27A) 17964.86 9.68 0 −0.489
IPI00017726 3-Hydroxyacyl-CoA dehydrogenase type-2 26923.03 7.65 0 0.227
IPI00220644 Pyruvate kinase isozymes M1/M2 41447.36 10.64 0 −0.132
Signaling proteins and receptor
IPI00555605 Peripheral plasma membrane protein CASK 104520.22 6.02 0 −0.426
IPI00402234 Ras-associated and pleckstrin homology
domains-containing protein 1 (RAPH1)
72873.77 5.91 0 −0.65
IPI00027462 Protein S100-A9 (S100A9) 13241.95 5.71 0 −0.895
IPI00017292 Catenin beta-1 (CTNNB1) 85496.55 5.53 0 −0.175
IPI00010470 Synaptosomal-associated protein 25 (SNAP25) 23315.08 4.66 0 −0.865
IPI00465156 Adenylate cyclase type 4 (ADCY4) 119794.61 7.31 12 0.152
Ion channel and transport protein
IPI00020542 Solute carrier family 22 member 11 (SLC22A11) 59971.64 8.96 10 0.463
IPI00007188 ADP/ATP translocase 2 (SLC25A5) 32895.2 9.76 3 0.045
IPI00031422 Sodium channel protein type 5 subunit alpha
(SCN5A)
224941.21 5.38 21 0.008
IPI00440493 ATP synthase subunit alpha, mitochondrial
(ATP5A1)
59750.67 9.16 0 −0.106
IPI00303476 ATP synthase subunit beta, mitochondrial
(ATP5B)
56559.96 5.26 0 −0.020
Cell cycle-associated proteins
IPI00784201 Centrosomal protein of 290 kDa (CEP290) 290544.28 5.75 0 −0.955
IPI00007765 Stress-70 protein, mitochondrial (HSPA9) 73680.41 5.87 0 −0.402




36053.05 8.57 0 −0.114
IPI00029009 Phosphatidylinositol-4-phosphate 5-kinase
type-1 gamma (PIP5K1C)
73260.32 5.17 0 −0.488
IPI00550128 Long-chain-fatty-acid–CoA ligase (ACSBG1) 81258.26 5.73 0 −0.263
Other annotated proteins
IPI00785084 Ig gamma-1 chain C region (IGHG1) 52286.28 8.84 0 −0.365
IPI00376931 Synaptotagmin-15 (SYT15) 52224.69 8.83 1 −0.258
IPI00292836 Uncharacterized protein C9orf174 (C9orf174) 191100.07 5.74 1 −0.648
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proteins were expressed at quite different levels in these two
cell lines, indicating the potential roles of these proteins in the
regulation of tumor progression. The gel was also stained with
silver iron for visualization (Fig. 1d). Then the silver-stained
bands corresponding to fluorescent-labeled bands were
matched in BGC-823 and GES-1 cells, and the protein bands
that are abundant for further LC-MS analysis were cut off
from the gel. These bands were indicated in Fig.1e as
green lines.
After LC-MS/MS analysis, 118 non-redundant proteins
were identified from BGC-823. Gene Ontology database
was utilized to analyze the subcellular localization of these
proteins. Among them, 89 proteins have their own clear posi-
tioning information in Gene Ontology database. These 89
proteins were classified into seven different categories accord-
ing to their subcellular location, including the plasma mem-
brane or membrane-associated proteins (36/89), nucleus pro-
teins (17/89), cytoplasmic proteins (19/89), secretory proteins
(9/89), mitochondrial proteins (4/89), cytoskeleton proteins
(3/89), and the endoplasmic reticulum proteins (1/89).
These 36 plasma membrane or membrane-associated
proteins were further analyzed by bioinformatics tools.
Firstly, the ProtParam software (http://www.expasy.org/
tools/protparam.html) was used to calculate the GRAVY
scores of these 36 proteins. Secondly, TMHMM version
2.0 (http://www.cbs.dtu.dk/services/TMHMM/) was used to
calculate the number of TMHs (trans-membrane helical
segments, TMHs) of these 36 proteins. Thirdly, the plasma
membrane or membrane-associated proteins fall into sev-
eral categories according to the biology function which
gained from gene-ontology (GO) database (http: //www.
geneontology.org/) (Fig. 2c). The physical property such
as molecular weight (MW) and isoelectric point (PI) of
these 36 membrane proteins were also analyzed. The char-
acteristic of these proteins was showed in Table 1. Among
all of these 36 proteins, the smallest and the biggest
β-actin
R-cadherin
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Fig 3 Expression of CDH4/R-cadherin in gastric cancer tissues and cell
lines. a, b qRT-PCR analysis of CDH4mRNA expression in N vs. Tof 17
GC patients. c, dWestern blot analysis of R-cadherin expression in N vs.
Tof 8 GC patients. T: GC tissues; N: the adjacent non-cancerous mucosa.
*P< 0.05, student t test. eWestern blot analysis of R-cadherin expression
in immortalized gastric epithelial cell GES-1 and three GC cell lines with
different degrees of differentiation and invasive
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protein molecular weights were 13.2 and 331.8 KDa, re-
spectively. The isoelectric point spreads from 4.65 to 10.
64 (Fig. 2a, b). The GRAVY score was between −0.955
and 0.463. There were 14 proteins which have more than
one TMD, and the most one named sodium channel pro-
tein type 5 subunit alpha is up to 21 (Table 1).
To learn more about the gene-related data including
genomic, transcriptomic, proteomic, genetic, clinical, and
functional information, these 36 membrane proteins were
put into GeneCards (http://www.genecards.org/), respectively.
According to the information provided byGeneCards database,
R-cadherin, a member of the cadherin superfamily which
identified from BGC-823, drew our great attention (protein
strip and mass spectrum were showed in Fig. 2d). R-cadherin
is a calcium-dependent cell-cell adhesion glycoprotein com-
prised of five extracellular cadherin repeats, a transmembrane
region and a highly conserved cytoplasmic tail. Based on
studies in chicken and mouse, this cadherin is thought to
play an important role during brain segmentation and neu-
ronal outgrowth. In addition, a role in kidney and muscle
development is indicated. However, its expression pattern
and biological function in GC ignition and progression re-
main unknown. Therefore, R-cadherin was selected for further
research below.
Low expression of R-cadherin is associated with the tumor
differentiation, pTNM stages
The expression of R-cadherin was first analyzed in clinic GC
tissues and GC cells. Results from qRT-PCR analysis indi-
cated that CDH4 mRNA levels in GC tissues were lower
than the paired adjacent non-cancerous mucosa in 88.2 %
(15/17) patients (Fig. 3a), and the difference was statistically
significant (P<0.05, Fig. 3b).
Results fromWestern blotting showed the expression of R-
cadherin was significantly lower in clinical GC tissues and GC
cell lines, as compared to the adjacent normal mucosa to
gastric carcinoma and the gastric epithelial cells, respectively
(Fig. 3c–e).
Tissue microarray immunohistochemistry results showed
R-cadherin protein expressed dominantly on cell surface of
GC and mucosal cells (Fig. 4a–e), similar to the previous
report in other tissues (GeneCards database). Its expression
deletion in gastric adenocarcinoma (142/169) was higher than
that of adjacent non-cancerous mucosa tissues (34/80). The
difference between the compared groups was statistically sig-
nificant (chi-square test, P<0.001).
Clinicopathological analysis revealed the expression of R-
cadherin protein was significantly negatively correlated with







Fig 4 R-cadherin expression in GC and non-cancerous tissues. aMucosa
of chronic gastritis; b Well-differentiated upper GC; c Middle-
differentiated upper GC; d Poor-differentiated distal GC (pT2N0M0); e
Poor-differentiated middle GC (pT2N3aM0); f Vascular cancer embolus
in pool-differentiated GC (pT1bN1M0)
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degree of tumor differentiation, lymph node metastasis, and
pTNM stage (chi-square test, P<0.05; Table 2). The patient’s
age, gender, and tumor size were not significantly different
between the R-cadherin negative and positive expressed
groups. Interestingly, R-cadherin expression deletion in upper
gastric adenocarcinoma (16/24) was lower than that of
middle and distal gastric cancer (126/145) with signifi-
cance (chi-square test, P<0.05; Table 2). In 16 cases of
vascular tumor emboli of gastric cancer, 81 % (13/16) of
them were R-cadherin negative expression (Fig. 4f).
Low expression of R-cadherin is associated with the poor
prognosis in GC
Kaplan-Meier analysis showed the patients with R-cadherin
positive expression displayed better overall survival than
those with negative expression (log-rank test, P < 0.01;
Fig. 5f and Table 3). Multivariate analysis by Cox regression
model revealed that lacking the expression of R-cadherin was
a major independent predictor for poor clinical outcome in GC
(RR=5.680, 95 % CI 2.250–14.341, P<0.01; Table 4).
Discussion
Membrane proteomic analysis has been proven to be a prom-
ising tool for identifying new and specific biomarkers that can
be used for prognosis and monitoring of various cancers [27].
At present, we knew little about the composition and the char-
acteristic of membrane proteins on the cell surface of GC.
Membrane proteins have hydrophobic feature; the fraction
of membrane proteins in whole cell extractions was quiet
low and not easy to be identified without contamination of
other intracellular proteins by general proteomic approaches.
Two-dimensional (2D) gel electrophoresis is a powerful
technology for protein abundance studies, and it was also
the only method available for simultaneous resolution of thou-
sands of proteins. The principle of 2D electrophoresis is based
on separation of the proteins according to their charge in the
first dimension by isoelectric focusing (IEF) and size in the
second dimension by SDS-PAGE. The 2-D DIGE is based on
fluorescence prelabeling of protein mixtures before 2D gel
electrophoresis. Protein samples are labeled with up to three
spectrally distinct charges and mass-matched fluorescent dyes
known as CyDye DIGE fluors (cy2/cy3/cy5) and make the
quantitative analysis of proteins in a gel. But, unfortunately,
it seems not easy to use for the quantitative analysis of mem-
brane proteins because the IEF has always been hampered by
the hydrophobic properties.
In order to overcome the deficiency of traditional proteo-
mic method which was used for cell surface proteomics study,
a series of methodological studies were performed in recent
years. In 2005, a new biotin-avidin chromatography-based
membrane proteomic strategy was established by Kazuto
Nunomura et al. [28]. In this method, the membrane proteins
exposed on intact ES cell surface were selectively labeled with
the membrane-impermeable reagent biotin first, then the bio-
tinylated plasmamembrane proteins were enriched via affinity
capture with immobilized avidin. After that, the biotinylated
proteins were separated by 1D SDS-PAGE electrophoresis
and identified by LC-MS. Using this method, a series of re-
ceptor, transport, and cell adhesion proteins were identified
from the undifferentiated mouse embryonic stem cell. In order
to further improve the efficiency and purity of membrane pro-
tein extraction and enrichment, Sidibe et al. [26] modified the
Kazuto Nunomura’s method in 2007. According to Sidibe’s
method, the vascular smooth muscle cells (SMCs) were
surface-labeled with CyDyes before the labeling of biotin,
using the features that fluorescent dyes can specifically tag
membrane proteins on the living cultured cell surface. Then,
the double-labeled membrane proteins were enriched on avi-
din column and subsequently separated on large format gra-
dient gels by SDS-PAGE and identified by LC-MS. Compare
to the method of Kazuto Nunomura’s, the prominent advan-
tage of this modified method is that CyDye DIGE fluors can
specifically target the ε2 site of surface exposed proteins and
Table 2 Correlationship between R-cadherin expression and clinico-
pathological variables
Clinicopathological variables R-cadherin ICH staining Chi-square test
Negative Positive P value
Gender
Male 98 19 0.889
Female 44 8
Age
≤60 76 11 0.223
>60 66 16
Tumor site
Upper 16 8 0.012
Middle and distal 126 19
Tumor size
≤5 cm 75 18 0.185
>5 cm 67 9
Differentiation
Well and moderate 26 11 0.010
Poor and undifferentiation 116 16
Invasion depth
T1-T2 31 10 0.091
T3-T4 111 17
Lymph node metastasis
Negative 29 12 0.008
Positive 113 15
pTNM stage
I–II 44 14 0.036
III–IV 98 13
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the fluorescent-labeled cell surface protein can be distin-
guished from other intracellular contaminants by fluorescence
tagging and permits semiquantitative differential expression
analysis. In this study, we adopted this modified method to
characterize the membrane proteome of GC.
Through this study, a total of 118 separate non-redundant
proteins have been identified from GC cell and 89 proteins
have the comment information in gene ontology database.
Among these 89 identified proteins, 36 were plasma mem-
brane proteins which include 9 adhesion and structural pro-
teins, 7 cell proliferation-, differentiation-, and apoptosis-
related proteins, 6 signal and receptor proteins, 5 channel
and transporters proteins, 3 cell cycle-related proteins, 3
metabolism-related proteins, and 3 other functional proteins.
According to the information of GeneCards database, 20 of
these plasma membrane proteins were specifically or domi-
nantly expressed on cell surface. The results of our study
further confirmed the reliability and efficiency of CyDye/
biotin-labeling approach for cell surface protein study and
provided a basic membrane proteome database for biological
studies of GC.
Cadherins play a key role in embryogenesis and tissue
homoeostasis. The dysregulation of cadherin expression such
as E-cadherin has been implicated in tumor progression and
metastasis [29, 30]. Apparently, there was a confirmed reports
that the loss of CDH1 (E-cadherin) expression in colorectal
cancer was associated with infiltrative tumor growth pattern
and lymph node metastasis [31].
There were more than 100 superfamily of transmembrane
cadherin proteins in human bodies [32]; elucidation of their
roles in suppression versus initiation or progression of various
tumor types is a young but fascinating field of molecular
cancer research [33, 34]. In our study, 2 novel cadherin
superfamily membranes, R-cadherin and protocadherin-15,
were identified from GC cell. In previous studies, R-
cadherin was considered as a key molecular in retinal
development [35], but its roles in tumorigenesis was dis-
covered in recent years. In 2004, Elenma Mitto [36] firstly
found CDH4, the encoding gene of R-cadherin, was dom-
inant methylated in colorectal cancer and GC. These epi-
genetic changes can also be detected in the patient’s pe-
ripheral blood, suggesting that CDH4 gene may play some
special roles in the initiation and progression of neoplasms
of digestive system. In 2008, Kucharczak [37] found that
the overexpression of R-cadherin in myoblast cell can af-
fect its endogenous N-cadherin and M-cadherin function
then inhibit myogenesis and induce myoblast transforma-
tion via Rac1 GTPase. In recent years, aberrant promoter
methylation of CDH4 was detected in both gastrointestinal
tumor and nasopharyngeal carcinoma, respectively [38–40],
which demonstrated CDH4 methylation may be a common
phenomenon in the process of tumorigenesis. CDH4 was
also considered as a potential tumor suppressor gene. In
this study, we found R-cadherin protein expression dele-
tion occurred in most of the GC samples, not in adjacent
non-cancerous mucosa.
Fig 5 Kaplan-Meier curves and log-rank test for the overall survival of GC patients according to age (a), tumor size (b), invasion depths (c), lymph node
metastasis (d), pTNM stage (e), and ICH staining of R-cadherin (f)
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In order to further understand the biological role of R-
cadherin in the initial and progression of GC, the relationship
between R-cadherin expression and the clinicopathological
variables were estimated in 169 GC tissues by immunohisto-
chemical analysis. We found that lacking the expression of R-
cadherin was correlated with the grade of cell differentiation,
lymph node metastasis, and pTNM stages of GC significantly.
In the Western blotting analysis between three GC cell lines
with different degrees of differentiation and invasive, we dis-
covered that the expression level of R-cadherin in moderate
differentiated gastric cancer cell line SGC-7901 was lower
than in immortalized gastric epithelial cell line GES-1.
Interestingly, further decreasing expression of R-cadherin oc-
curred in poorly differentiated gastric cancer cell line BGC-
823, as well as complete deletion can be seen in gastric mu-
cous adenocarcinoma cell line MGC-803. This founding sug-
gested that the expression level of R-cadherin was associated
with differentiation and malignant degrees of GC, which was
similar to its trends and characteristics in breast cancer [41],
further indicating its role of tumor suppressor gene.
In order to estimate its prognostic value for GC, Kaplan-
Meier analysis and log-rank test were adopted to compare the
difference of clinical outcome of GC patients with R-cadherin
positive and negative expression. Our results indicate that the
gastric patients with R-cadherin positive expression have a




Clinicopathological variables Patient events Median survival months Log-rank test
(95 % CI, %) P value
Gender
Male 84 65 21 (15.8–26.2) 0.936
Female 39 30 22 (15.9–28.1)
Age
≤60 66 49 27 (20.8–33.2) 0.042
>60 57 46 15 (10.1–19.9)
Tumor size
≤5 cm 68 50 28 (22.6–33.4) 0.038
>5 cm 55 45 16 (11.5–20.5)
Differentiation
Well and moderate 29 20 23 (17.7–28.3) 0.345
Poor and undifferentiation 94 75 21 (16.7–25.3)
Invasion depth
T1-T2 29 12 NA 0.000
T3-T4 94 83 19 (14.7–23.3)
Lymph node metastasis
Negative 26 11 NA 0.000
Positive 97 84 19 (15.3–22.7)
pTNM stage
I–II 38 23 46 (29.4–62.6) 0.000
III–IV 85 72 18 (14.4–21.6)
R-cadherin ICH staining
Negative 109 90 19 (15.6–22.4) 0.000
Positive 14 5 NA
NA, because the overall survival rates of these patients were more than 50 %, the median survival time cannot be
calculated
Table 4 Cox proportional hazard regression model analysis of all the
patients
Clinicopathological variables Multivariate analysis
Age Relative risk 95 % CI P value
≤60 vs. >60 0.570 0.376–0.864 0.008
Tumor size
≤5 cm vs. >5 cm 0.911 0.591–1.405 0.673
Invasion depth
T1-T2 vs. T3-T4 0.340 0.176–0.655 0.001
Lymph node metastasis
Negative vs. positive 0.495 0.244–1.002 0.051
pTNM stage
I–II vs. III–IV 0.865 0.500–1.496 0.604
R-cadherin expression
Negative vs. positive 5.680 2.250–14.341 0.000
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better 5-year overall survival than those with negative expres-
sion. In order to eliminate the interference of other clinical
variables in the survival analysis, Cox proportional hazard
regression model adjusting age, tumor size, invasion depth,
lymph node metastasis, and pTNM stage showed the same
trend as the Kaplan-Meier survival curve. R-cadherin expres-
sion deletion was considered as a major independent predictor
for worse outcome in GC (RR= 5.680, 95 % CI 2.250–
14.341, P<0.01).
Protocadherin-15, another member of the cadherin super-
family, is an essential protein in the maintenance of normal
retinal and cochlear function. Mutations in this gene will result
in hearing loss and Usher syndrome [42, 43]. Currently, a new
secreted protocadherin-15 isoform was identified from NK/T
cell lymphomas, and it can be used as a potential cell marker
[44]. In our study, protocadherin-15 was also identified from
BGC-823 GC cell. It could be detected in gastric cell lines
using immunochemistry, but its subcellular localization was
ambiguous and the results of the Western blotting are not very
stable (results were not shown in this paper), which need to be
further validated by more excellent antibodies and high-
volume clinic GC tissues.
Besides adhesion molecules, many other types of cell
surface proteins were also identified from GC cell in our
study. Some of them have been reported previously in GC
studies [45–47], most of them have not yet been fully
explored. The biological role of these proteins remains to
be further investigated.
In summary, we have established a fundamental membrane
proteomic database of GC. R-cadherin has been identified as a
novel tumor differentiation- and progression-related cell sur-
face marker. Its expression deletion in gastric cancer predicts
poor clinic outcome.
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